CompletedNCT05179525
Comparing two risperidone formulations for schizophrenia care
About this title
Read the official source — NCT05179525Medication studyAges 18–65United States
Understand this study
Who was this study for?
Listed age limits: 18 years to 65 years.
- Listed locations
- Garden Grove and 3 more locationsSee all locations and recruitment
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
Study information
Study start dateStarted: March 9, 2021
- Recruitment status
- Completed
- Enrollment listed in the registry
- 80
- Sponsor
- Rovi Pharmaceuticals Laboratories
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Drug
- Study phase
- Phase 1Usually an early study focused on safety, tolerability, dosage, and side effects.
- Locations
- United States
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT05179525
- Official title
Show the full official title
An Open-Label, One-Sequence Study to Evaluate the Steady- State Comparative Bioavailability of Intramuscular Risperidone ISM® and EU Risperdal® (Sourced From Germany)
Looking for a study you can join?
Explore recruiting studiesRecruitment & locations
CompletedThis badge reflects the study status reported by the registry. Check the registry for the latest information.
Garden Grove · Gaithersburg · Berlin
1 more locations
- DeSoto
Interested in joining this study?
Questions about this study
Who is behind this study?
The study sponsor is Rovi Pharmaceuticals Laboratories, a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including Risperidone ISM® 100 mg and Risperdal 4mg Tablet.
Who was this study for?
Listed age limits: 18 years to 65 years.
